TP53 mutations in malignant and premalignant Barrett’s esophagus
- 1 June 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 16 (2) , 83-89
- https://doi.org/10.1046/j.1442-2050.2003.00302.x
Abstract
Summary. In order to improve the efficacy of endoscopic surveillance of Barrett’s esophagus, markers of neoplastic progression in addition to dysplasia are reqKeywords
This publication has 37 references indexed in Scilit:
- Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmationHuman Pathology, 2001
- Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational studyBMJ, 2000
- Practice Guidelines on the Diagnosis, Surveillance, and Therapy of Barrett's EsophagusAmerican Journal of Gastroenterology, 1998
- Cost effectiveness of detecting Barrett's cancer.Gut, 1996
- Barrett's Esophagus with High-Grade DysplasiaAnnals of Surgery, 1996
- The Rationale for Esophagectomy as the Optimal Therapy for Barrett's Esophagus with High-Grade DysplasiaAnnals of Surgery, 1996
- Barrett's esophagus with high-grade dysplasia: An indication for esophagectomy?The Annals of Thoracic Surgery, 1992
- Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.Gut, 1991
- Barrett's Esophagus; Development of Dysplasia and AdenocarcinomaGastroenterology, 1989
- Observer variation in the diagnosis of dysplasia in Barrett's esophagusHuman Pathology, 1988